Q3 EPS Estimate for Alpha Tau Medical Decreased by Analyst

Key Points

• HC Wainwright lowered Alpha Tau Medical’s Q3 2026 EPS estimate to a loss of $0.15 per share from $0.14, while maintaining a “Buy” rating and $16 price target.
• Alpha Tau Medical reported a quarterly loss of $0.50 per share, significantly missing the $0.14 consensus estimate, while revenue of $0.10 million also fell short of expectations.
• Analyst sentiment remains broadly positive, with five Buy, two Hold, and one Sell ratings; the stock has a “Moderate Buy” consensus and an average price target of $12.80.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Alpha Tau Medical in a research report issued on Tuesday, August 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.15) for the quarter, down from their prior forecast of ($0.14). HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Alpha Tau Medical's current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Alpha Tau Medical's Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.60) EPS.

Several other research firms have also weighed in on DRTS. Weiss Ratings restated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Barclays lifted their price target on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday, June 4th. Zacks Research raised Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research report on Monday, August 3rd. LADENBURG THALM/SH SH lifted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, May 12th. Finally, Piper Sandler increased their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the company a "neutral" rating in a research note on Tuesday, May 19th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $12.80.

Alpha Tau Medical Stock Performance

Shares of DRTS stock opened at $13.87 on Thursday. The company has a fifty day moving average price of $11.75 and a two-hundred day moving average price of $9.27. Alpha Tau Medical has a one year low of $3.00 and a one year high of $14.40. The stock has a market cap of $1.25 billion, a P/E ratio of -13.34 and a beta of 1.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.14 million.

Institutional Trading of Alpha Tau Medical

Several hedge funds have recently modified their holdings of DRTS. Mariner LLC increased its stake in Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company's stock valued at $620,000 after purchasing an additional 1,915 shares in the last quarter. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical in the 4th quarter valued at about $48,000. Everhart Financial Group Inc. bought a new position in Alpha Tau Medical in the second quarter worth approximately $126,000. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical in the 3rd quarter worth $62,000. Finally, Wells Fargo & Company MN raised its holdings in Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock worth $116,000 after buying an additional 17,500 shares during the last quarter. Institutional investors own 2.65% of the company's stock.

Insider Transactions at Alpha Tau Medical

In other news, CFO Raphi Levy sold 32,500 shares of the business's stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00. Following the sale, the chief financial officer directly owned 147,680 shares in the company, valued at approximately $1,599,374.40. The trade was a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 130,000 shares of company stock worth $1,519,143. 39.50% of the stock is owned by corporate insiders.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source